Mustang Bio, Inc. (MBIO)

NASDAQ: MBIO · IEX Real-Time Price · USD
1.55
+0.11 (7.64%)
At close: Dec 7, 2023, 4:00 PM
1.56
+0.01 (0.65%)
After-hours: Dec 7, 2023, 6:42 PM EST
7.64%
Market Cap 13.27M
Revenue (ttm) n/a
Net Income (ttm) -62.62M
Shares Out 8.37M
EPS (ttm) -7.99
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 64,583
Open 1.47
Previous Close 1.44
Day's Range 1.41 - 1.65
52-Week Range 1.25 - 11.09
Beta 1.76
Analysts Strong Buy
Price Target 19.67 (+1,169.03%)
Earnings Date Nov 14, 2023

About MBIO

Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors. The company develops MB-107 and MB-207, a gene therapy program for X-linked severe combined immunodeficiency, a rare g... [Read more]

Industry Biotechnology
Sector Healthcare
CEO Dr. Manuel Litchman M.D.
Employees 113
Stock Exchange NASDAQ
Ticker Symbol MBIO
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 3 analysts, the average rating for MBIO stock is "Strong Buy." The 12-month stock price forecast is $19.67, which is an increase of 1,169.03% from the latest price.

Price Target
$19.67
(1,169.03% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Mustang Bio Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights

WORCESTER, Mass., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cel...

23 days ago - GlobeNewsWire

Mustang Bio Announces MB-106 CD20-Targeted CAR-T Data Selected for Presentation at 65th American Society of Hematology (ASH) Annual Meeting

Updated interim data from Mustang's multicenter Phase 1/2 clinical trial demonstrate favorable safety and efficacy profile of MB-106 in heavily pre-treated lymphoma patients Updated interim data from ...

5 weeks ago - GlobeNewsWire

Mustang Bio Announces Closing of $4.4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

WORCESTER, Mass., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical bre...

5 weeks ago - GlobeNewsWire

Mustang Bio Announces $4.4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

WORCESTER, Mass., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical bre...

6 weeks ago - GlobeNewsWire

Mustang Bio Announces FDA Acceptance of IND Application for MB-109, a Novel Combination of MB-101 (IL13Rα2‐targeted CAR-T cell therapy) and MB-108 (HSV-1 oncolytic virus), for the Treatment of Recurrent Glioblastoma and High-Grade Astrocytoma

MB‐101 (IL13Rα2‐targeted CAR-T cell therapy) and MB-108 (HSV-1 oncolytic virus) are separately well tolerated in patients with recurrent GBM in ongoing Phase 1 clinical trials; preclinical data suppor...

6 weeks ago - GlobeNewsWire

Mustang Bio to Participate in Upcoming September 2023 Investor Conferences

WORCESTER, Mass., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in ce...

3 months ago - GlobeNewsWire

Mustang Bio Announces First Data from Ongoing Multicenter Phase 1/2 Clinical Trial Evaluating MB-106 CAR-T Cell Therapy

Initial data show clinical responses from four of four indolent lymphoma patients, including complete response in follicular lymphoma patient previously treated with CD19 CAR-T cell therapy

4 months ago - GlobeNewsWire

Mustang Bio Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights

WORCESTER, Mass., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cel...

4 months ago - GlobeNewsWire

Mustang Bio to Participate in Two August 2023 Investor Conferences

WORCESTER, Mass., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cel...

4 months ago - GlobeNewsWire

Mustang Bio Announces Amendment and Closing of Strategic Manufacturing Partnership Transaction with uBriGene (Boston) Biosciences

Transaction and reduction in operating expenses enhance Mustang's cash position Transaction and reduction in operating expenses enhance Mustang's cash position

4 months ago - GlobeNewsWire

Mustang Bio Announces Participation in Upcoming Scientific Meetings

Management team to speak at 2nd In Vivo Engineering of Therapeutic Cells Summit and 8th Annual CAR-TCR Summit Management team to speak at 2nd In Vivo Engineering of Therapeutic Cells Summit and 8th An...

5 months ago - GlobeNewsWire

Mustang Bio Announces Final Results from Follicular Lymphoma Cohort of Single-Institution Phase 1/2 Clinical Trial of MB-106, CD20-Targeted Autologous CAR T Therapy

10 out of 20 patients remain in complete remission for more than a year 95% overall response rate (ORR) and 80% complete response (CR) rate across all patients; 100% ORR and 91% CR with higher dose le...

6 months ago - GlobeNewsWire

Mustang Bio Announces Updated Results from Waldenstrom Macroglobulinemia Cohort of Ongoing Phase 1/2 Clinical Trial of MB-106, CD20-Targeted Autologous CAR T Therapy

MB-106 continues to demonstrate favorable safety and efficacy profile Overall response rate of 83% in cohort with durable responses observed; one patient remains in complete remission at 22 months All...

6 months ago - GlobeNewsWire

Mustang Bio Announces Strategic Manufacturing Partnership and Portfolio Updates

uBriGene (Boston) Biosciences to acquire Mustang Bio's Worcester manufacturing facility for total consideration of up to $11 million and enters into strategic manufacturing partnership to support MB-1...

7 months ago - GlobeNewsWire

Mustang Bio Reports First Quarter 2023 Financial Results and Recent Corporate Highlights

WORCESTER, Mass., May 12, 2023 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell...

7 months ago - GlobeNewsWire

Mustang Bio Announces Upcoming Presentations of Clinical Data from Phase 1/2 Trial of MB-106, a CD20-Targeted Autologous CAR T Cell Therapy

Data from Waldenstrom macroglobulinemia cohort selected for poster presentation at EHA2023 Outpatient treatment of follicular lymphoma selected for oral presentation at ICML WORCESTER, Mass., May 11, ...

7 months ago - GlobeNewsWire

Mustang Bio Announces Reverse Stock Split

WORCESTER, Mass., April 03, 2023 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical br...

8 months ago - GlobeNewsWire

Mustang Bio Reports Full-Year 2022 Financial Results and Recent Corporate Highlights

WORCESTER, Mass., March 29, 2023 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in ce...

9 months ago - GlobeNewsWire

Mustang Bio to Participate in Cantor's The Future of Oncology Virtual Symposium

WORCESTER, Mass., March 28, 2023 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical br...

9 months ago - GlobeNewsWire

Mustang Bio to Participate in the B. Riley Securities' 3rd Annual Oncology Conference

WORCESTER, Mass., Jan. 17, 2023 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical bre...

11 months ago - GlobeNewsWire

Mustang Bio Provides CAR T Cell Therapy Portfolio Updates and 2023 Anticipated Milestones

MB-106 clinical trial under Mustang's IND continues to enroll patients

1 year ago - GlobeNewsWire

Mustang Bio Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights

WORCESTER, Mass., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cel...

1 year ago - GlobeNewsWire

Mustang Bio to Participate in Upcoming September 2022 Investor Conferences

WORCESTER, Mass., Sept. 08, 2022 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in ce...

1 year ago - GlobeNewsWire